XBiotech recently announced a transaction with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, in which it sold them its novel true human antibody bermekimab. Bermekimab neutralizes interleukin-1 alpha (IL-1⍺), which promotes disease-causing inflammation in a wide range of medical conditions. As part of this transaction Janssen acquired all rights to bermekimab, and XBiotech is free to use its True Human Antibody discovery program to develop new antibody therapeutics that target IL-1⍺ to treat non-dermatological diseases. XBiotech plans to expeditiously re-enter clinical development with a next generation anti-IL-1⍺ therapeutic.
Bermekimab has had success in the clinic in a wide array of indications. Publications from clinical studies involving bermekimab are listed below. XBiotech believes IL-1⍺ is a truly remarkable target that has potential to treat patients on a global scale for a number of chronic and acute inflammatory conditions, including heart disease, heart attack, stroke, rheumatological disease, gastrointestinal diseases, and cancer. The Company is excited to pursue these indications with its next generation IL-1⍺ neutralizing therapeutic.